TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06786975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Tooth will be isolated with cotton rolls, the oral cavity will be dried with small cotton balls and the gingiva around the tooth, and surrounding structures, will be protected with vaseline. Then the silver diamine fluoride solution will be applied to cavitated caries lesions with a micro applicator for one minute approximately. If necessary the solution excess should be removed with a gauze.~Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: Participants will be treated with Atraumatic Restorative Treatment (ART) technique. Glass ionomer will be used for cavity filling (Ketac MolarTM, 3M ESPETM) according to manufacter specifications and will be applied with a spatula, followed by finger pressure using vaseline for a few seconds; for occluso-proximal cavities, a matrix band will be used. The restoration will be protected with vaseline and then the occlusion will be checked with articular paper after the initial adjustment (approximately 5 minutes). Finally the child's teacher will be given the indications for the child to not eat, drink or rinse up to 30 minutes after the treatment, and to evaluate if any sign or symptom related to the tooth appears.
Study: NCT05688423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIRI Team
Description: Participants randomized to the intervention will receive integrated ID and SUD care (SIRI Team) both during the hospitalization and after hospital discharge for 4 months post-randomization. The intervention is based upon six general principles for treating PWID with infectious complications and is informed by harm reduction.~1. Medications for SUD as integral to management of infectious complications~2. Integration of ID and SUD care~3. Longitudinal care with familiar providers~4. Multidisciplinary care and care coordination~5. Tailored antibiotic options and care settings~6. Harm reduction
Study: NCT04802681

Intervention type: DEVICE
Group type: OTHER
Intervention: FFR-measurement with different pressure guidewires
Description: Measuring FFR with different pressure guidewires
Study: NCT05688423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants assigned to the TAU group will receive the standard treatment for their severe injection-related infection and substance use disorder at each hospital. While TAU may differ between sites, it is typically comprised of a patient being cared for primarily by a hospital medicine physician (hospitalist) with consultation by infectious diseases (ID) and either psychiatry or addiction medicine physician. If the ID or addiction teams believe post-hospitalization follow up is indicated, each service will follow local protocols for arranging post-discharge continuation of care.
Study: NCT06520384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Patients will receive radiofrequency.
Study: NCT06106009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, oral suspension or solid oral formulation(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral solution
Study: NCT06185907

Intervention type: OTHER
Intervention: Surgery
Description: We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.
Study: NCT06084182

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive function, cognitive reserve, functional capacity, reaction time, strength, fatigue, depression and general health assessment
Description: 6-minute walk test and 5-time sit-to-stand test (STS-5) were used for functional capacity assessment. For cognitive reserve assessment, the Cognitive Reserve Index questionnaire was used. Reaction time, cognitive function and visiospatial perception were evaluated with the mobile application. In addition, the Fatigue Severity Scale; Beck Depression Questionnaire and Nottingham Health Profile were used.
Study: NCT04806776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24hrs dressings change
Description: The first dressing change and sampling were completed 24 hours after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..Then the second dressing change and sampling were completed 7days later(if there is no clinical indication occur,such leaking,blood).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7days dressings change
Description: The first dressing change and sampling were completed 7 days after catheterization in the operating room or PICU.When bedside nurse remove the dressing ,the researchers used 4 normal saline cotton swabs to wipe the skin under the dressing. Taking the puncture point as the center, 4 cotton swabs wipes 4 points in the northwest, northeast, Southeast and northeast direction 1cm away from the puncture point,separately.Then the specimen delivered to Laboratory..(if there is no clinical indication occur,such leaking,blood).
Study: NCT05325554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation
Description: Multimodal rehabilitation
Study: NCT05657314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: Consists of 15 grams of pea protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Consists of 15 grams of pea protein
Study: NCT06520384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol 30%
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol 50%
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol 70%
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
Study: NCT06185296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent telemonitoring
Description: Telemonitoring using CGM, insulin pen data, and Fitbit data supported by data-driven decision support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: Telemonitoring using CGM, insulin pen data, and Fitbit data
Study: NCT05097001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DBS programming
Description: DBS readjustment based on COMPUTER or CLINICAL program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS programming
Description: DBS readjustment based on COMPUTER or CLINICAL program
Study: NCT05035316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: Oral tablet: acetylsalicylic acid,150 mg, 1 tablet/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: Oral tablet: calcium, 1 tablet/day
Study: NCT06078384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 mg/ml
Description: Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Injectable solution for IV administration. Dose of 80 mg/m² weekly.
Study: NCT05204381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-frequency near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-frequency near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a near-zero phase lag.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-frequency anti-synchrony stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-frequency anti-synchrony stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in theta-frequency (approximately 6 Hz) with a 180 degree phase offset, anti-synchrony.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in an arrhythmic pattern with a near-zero phase lag matched in duration to the rhythmic stimulation for that session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic independent stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic independent stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in different independent arrhythmic patterns matched in duration to the rhythmic stimulation for that session.
Study: NCT06171763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The telehomecare solution involves an early discharge with continued home monitoring through the use of telemedicine utilizing an user-friendly mobile. Additionally, there were a clinical reassessment in person 72 hours after discharge to evaluate the outcomes and results of the intervention.
Study: NCT05130177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.
Study: NCT04648631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: antibiofilm surfactant wound gel (ABWG)
Description: ABWG is a hydro-gel applied topically using a tongue depressor
Study: NCT05288075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indacaterol/glycopyrronium
Description: In each period, subjects receive single dose of indacaterol/glycopyrronium consisting of 2 inhaled doses via Easyhaler or 2 capsules inhaled via Ultibro Breezhaler.~In addition to study treatments, activated charcoal will be administered on each study period before and after study drug administration.
Study: NCT05204381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-frequency near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-frequency near-zero phase lag stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a near-zero phase lag.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-frequency anti-synchrony stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
Study: NCT05359796

Intervention type: BIOLOGICAL
Intervention: Chronic hyperglycemia
Description: For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.

Intervention type: BIOLOGICAL
Intervention: Residual islet function
Description: For each follow-up, fasting and stimulated C-peptide levels will be measured.

Intervention type: GENETIC
Intervention: Genetic variation
Description: Genetic variations of interest will be detected with the blood sample collected at baseline.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Dietary constitutes
Description: For each follow-up, the dietary constitutes for the past 3 days will be recorded.

Intervention type: GENETIC
Intervention: Microbiome composition and function
Description: For each follow-up, the fecal and oral samples will be collected for measurement.

Intervention type: BIOLOGICAL
Intervention: Metabolome composition
Description: For each follow-up, the serum and urine samples will be collected for measurement.

Intervention type: BIOLOGICAL
Intervention: Composition of peripheral blood immune cells
Description: For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.
Study: NCT06079164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-197
Description: A single infusion of CAR-transduced autologous T cells administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy administered intravenously
Study: NCT04231279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: synthetic human secretin
Description: Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic human secretin
Description: Secretin is a gastrointestinal peptide hormone, indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction.
Study: NCT05793996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: The calculation of the dose of iron carboxymaltosate (Ferinject ® preparation) for the purpose of correction of iron will be carried out on the basis of the following step-by-step approach: determination of individual iron needs, calculation and administration of iron dose, assessment of the saturation of the patient's body with iron 6 weeks after infusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet therapy
Description: Patients will receive diet therapy to correct latent iron deficiency
Study: NCT03650374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Rehabilitation
Description: Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Strength Training
Description: Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
Study: NCT05289141

Intervention type: DEVICE
Intervention: Use of high flow nasal oxygen therapy
Description: Use of high flow nasal oxygen therapy during secondary transport by emergency medical service 83 (SAMU 83).

Intervention type: DEVICE
Intervention: Use of other non-invasive ventilation or high concentration oxygen masks
Description: Use of other non-invasive ventilation or high concentration oxygen masks during secondary transport by emergency medical service 83 (SAMU 83).
Study: NCT05116319

Intervention type: DIAGNOSTIC_TEST
Intervention: point-of-care HbA1c
Description: The Afinion2™ (Abbott, Oslo, Norway), will be used for the current study as it is recently validated. According to American Diabetes Association (ADA), pre-diabetes (pre-DM) is diagnosed if HbA1c is 5.7-6.4% and diabetes (DM) is diagnosed if HbA1c is ≥6.5%
Study: NCT05872542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Description: Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply SDF to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Remove excess SDF with gauze or cotton pellets. Continue to isolate the site for up to three minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Restoration (GI)
Description: Application of GI restoration necessitates removal of carious tissue using round bur rotating on low-speed contra and excavation of infected carious dentin. Followed by restoring the prepared cavity with glass ionomer restoration according to the manufacturer's instructions. The restoration will be checked for any high spots and occlusal interference (if any) will be corrected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish with nano-sliver particles (NaF-AgNP)
Description: Proper isolation of the operating field and removal of gross debris. Minimize contact with the gingiva and mucus membrane. Gentle dryness with compressed air. Dip and dab micro brush on the side of the dapper dish. Apply NaF-AGNP to the affected surface (one drop/ appointment). Gentle dryness with compressed air for one minute. Continue to isolate the site for up to three minutes.
Study: NCT06198712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Participants will receive oral tablets of etavopivat once daily.
Study: NCT05204381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-frequency anti-synchrony stimulation
Description: Rhythmic transcranial magnetic stimulation (TMS) is delivered to both frontal and parietal cortex in alpha-frequency (approximately 10 Hz) with a 180 degree phase offset, anti-synchrony.
Study: NCT05477576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RYZ101
Description: RP3D as determined in Phase 1b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RYZ101
Description: RP3D as determined in Phase 1b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Sunitinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: High-dose octreotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide
Description: Lanreotide